Profile: Biomedica Diagnostics Inc. focuses on medical diagnostic solutions. We manufacture chemical reagent kits and equipment for health diagnostics. Our Danam semi-automated 18-parameter cell counter provides a test range of WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, MPV, PCT, PDW and PLT. The system also displays WBC histogram, PLT histogram and RBC histogram. The sample size varies from 25 to 125 µL, and stores up to 200 patient results. Our urinalysis strip is a tool for rapid analysis of carbohydrate metabolism, kidney & liver functions and acid-base balance. It measures glucose, pH, proteins, ketones, blood, bilirubin, nitrates, urobilinogen, specific gravity and leukocytes. Our latex agglutination tests provide rapid, reliable results in minutes, without any additional instrumentation.
The company is ISO 13485 certified.
FDA Registration Number: 3003691680
US Agent: Kirk Guyer / Cascade Technologies Inc.
Phone: +1-(574)-532-9957 E-Mail:
9 Products/Services (Click for related suppliers)
|
• Activated Partial Thromboplastin (FDA Code: GFO / 864.7925) A partial thromboplastin time test is a device used for primary screening for coagulation abnormalities, for evaluation of the effect of therapy on procoagulant disorders, and as an assay for coagulation factor deficiencies of the intrinsic coagulation pathway. |
• Binocular Microscope |
• Blood Analyzer Reagents |
• Centrifuge Aids |
• Centrifuges |
• Coagulation Analyzers (FDA Code: GKP / 864.5400) A coagulation instrument is an automated or semiautomated device used to determine the onset of clot formation for in vitro coagulation studies. |
• Hematology Reagents |
• Plasma Coagulation Control (FDA Code: GGN / 864.5425) A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays. |
• Prothrombin Time Test (FDA Code: GJS / 864.7750) A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism). |